Table 1.

Comparison of changes in areal and volumetric BMD and in estimated bone strength over 12 months of therapy with romosozumab and teriparatide.

	Reference	Romosozumab 210 mg QM	Teriparatide 20 μg/d
Areal BMD (DXA)
Lumbar spine	[12]	12.3%a	6.9%
Total hip		3.9%a	0.8%
Integral volumetric BMD (QCT)
Lumbar spine	[12]	17.7%a	12.9%
Total hip		4.1%a	1.2%
Estimated bone strength (FEA by QCT)
Lumbar spine	[13]	27.3%a	18.5%
Total hip		3.6%a	−0.7%

BMD, bone mineral density; QM, once monthly; DXA, dual-energy X-ray absorptiometry; QCT, quantitative computed tomography; FEA, finite element analysis.

^ap ≤ 0.05 vs. teriparatide.